OncoMatch/Clinical Trials/NCT05873686
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Is NCT05873686 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies NXP900 for advanced solid tumor.
Treatment: NXP900 — This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Renal Cell Carcinoma
Mesothelioma
Biomarker criteria
Required: YES1 amplification
YES1 amplification (NSCLC adenocarcinoma or squamous cell carcinoma; other solid tumors)
Required: TYMS amplification
TYMS amplification (NSCLC adenocarcinoma or squamous cell carcinoma; other solid tumors)
Required: FAT1 pathogenic mutation
FAT1 pathogenic mutation (NSCLC adenocarcinoma or squamous cell carcinoma; other solid tumors)
Required: NF2 pathogenic mutation
NF2 pathogenic mutation (renal cancer, mesothelioma, other solid tumors)
Required: LATS1 pathogenic mutation
LATS1 pathogenic gene mutation (other solid tumors)
Required: YAP1 amplification
YAP1 gene amplification (other solid tumors)
Required: TAZ1 amplification
TAZ1 gene amplification (other solid tumors)
Required: IDH1 mutation
cholangiocarcinoma with IDH1 or IDH2 mutations
Required: IDH2 mutation
cholangiocarcinoma with IDH1 or IDH2 mutations
Excluded: HER2 (ERBB2) overexpression
Subjects with known human epidermal growth factor receptor 2 (HER2+) overexpressing malignancies
Excluded: BRAF mutation
Subjects with colorectal cancer, glioma, melanoma, or anaplastic thyroid conditions with BRAF mutations
Excluded: BRAF mutation
Subjects with NSCLC with BRAF or EGFR mutations or HER2 overexpression
Excluded: EGFR mutation
Subjects with NSCLC with BRAF or EGFR mutations or HER2 overexpression
Excluded: HER2 (ERBB2) overexpression
Subjects with NSCLC with BRAF or EGFR mutations or HER2 overexpression
Excluded: HER2 (ERBB2) alteration
Subjects with breast cancer, gastric cancer, esophageal junction adenocarcinoma or biliary cancer with HER2 alterations
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic · Phoenix, Arizona
- UC San Diego Moores Cancer Center · La Jolla, California
- Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Mayo Clinic · Jacksonville, Florida
- University of Chicago · Chicago, Illinois
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05873686 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require YES1?
Yes, YES1 amplification is a required biomarker for enrollment.
Does this trial require TYMS?
Yes, TYMS amplification is a required biomarker for enrollment.
Does this trial require FAT1?
Yes, FAT1 pathogenic mutation is a required biomarker for enrollment.
Are patients with ERBB2 alterations eligible?
No. ERBB2 overexpression is an exclusion criterion.
Are patients with BRAF alterations eligible?
No. BRAF mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify